ID   ACER2_HUMAN             Reviewed;         275 AA.
AC   Q5QJU3; A2A3R8; Q569G5; Q5VZR7; Q71RD2;
DT   25-JUL-2006, integrated into UniProtKB/Swiss-Prot.
DT   25-JUL-2006, sequence version 2.
DT   10-MAY-2017, entry version 96.
DE   RecName: Full=Alkaline ceramidase 2;
DE            Short=AlkCDase 2;
DE            Short=Alkaline CDase 2;
DE            Short=haCER2;
DE            EC=3.5.1.23;
DE   AltName: Full=Acylsphingosine deacylase 3-like;
DE   AltName: Full=N-acylsphingosine amidohydrolase 3-like;
GN   Name=ACER2; Synonyms=ASAH3L; ORFNames=PP11646;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, SUBCELLULAR
RP   LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=16940153; DOI=10.1096/fj.05-5689com;
RA   Xu R., Jin J., Hu W., Sun W., Bielawski J., Szulc Z., Taha T.,
RA   Obeid L.M., Mao C.;
RT   "Golgi alkaline ceramidase regulates cell proliferation and survival
RT   by controlling levels of sphingosine and S1P.";
RL   FASEB J. 20:1813-1825(2006).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RX   PubMed=15498874; DOI=10.1073/pnas.0404089101;
RA   Wan D., Gong Y., Qin W., Zhang P., Li J., Wei L., Zhou X., Li H.,
RA   Qiu X., Zhong F., He L., Yu J., Yao G., Jiang H., Qian L., Yu Y.,
RA   Shu H., Chen X., Xu H., Guo M., Pan Z., Chen Y., Ge C., Yang S.,
RA   Gu J.;
RT   "Large-scale cDNA transfection screening for genes related to cancer
RT   development and progression.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:15724-15729(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   FUNCTION.
RX   PubMed=18945876; DOI=10.1096/fj.08-115634;
RA   Sun W., Hu W., Xu R., Jin J., Szulc Z.M., Zhang G., Galadari S.H.,
RA   Obeid L.M., Mao C.;
RT   "Alkaline ceramidase 2 regulates beta1 integrin maturation and cell
RT   adhesion.";
RL   FASEB J. 23:656-666(2009).
RN   [6]
RP   FUNCTION, ENZYME REGULATION, BIOPHYSICOCHEMICAL PROPERTIES,
RP   SUBCELLULAR LOCATION, AND TOPOLOGY.
RX   PubMed=20089856; DOI=10.1074/jbc.M109.069203;
RA   Sun W., Jin J., Xu R., Hu W., Szulc Z.M., Bielawski J., Obeid L.M.,
RA   Mao C.;
RT   "Substrate specificity, membrane topology, and activity regulation of
RT   human alkaline ceramidase 2 (ACER2).";
RL   J. Biol. Chem. 285:8995-9007(2010).
CC   -!- FUNCTION: Hydrolyzes the sphingolipid ceramide into sphingosine
CC       and free fatty acid. Unsaturated long-chain ceramides are the best
CC       substrates, saturated long-chain ceramides and unsaturated very
CC       long-chain ceramides are good substrates, whereas saturated very
CC       long-chain ceramides and short-chain ceramides were poor
CC       substrates. The substrate preference is D-erythro-C(18:1)-,
CC       C(20:1)-, C(20:4)-ceramide > D-erythro-C(16:0)-, C(18:0), C(20:0)-
CC       ceramide > D-erythro-C(24:1)-ceramide > D-erythro-C(12:0)-
CC       ceramide, D-erythro-C(14:0)-ceramides > D-erythro-C(24:0)-ceramide
CC       > D-erythro-C(6:0)-ceramide. Inhibits the maturation of protein
CC       glycosylation in the Golgi complex, including that of integrin
CC       beta-1 (ITGB1) and of LAMP1, by increasing the levels of
CC       sphingosine. Inhibits cell adhesion by reducing the level of ITGB1
CC       in the cell surface. May have a role in cell proliferation and
CC       apoptosis that seems to depend on the balance between sphingosine
CC       and sphingosine-1-phosphate. {ECO:0000269|PubMed:16940153,
CC       ECO:0000269|PubMed:18945876, ECO:0000269|PubMed:20089856}.
CC   -!- CATALYTIC ACTIVITY: N-acylsphingosine + H(2)O = a carboxylate +
CC       sphingosine.
CC   -!- ENZYME REGULATION: Specifically activated by lumenal, but not
CC       cytosolic Ca(2+). Inhibited by Zn(2+) or Cu(2+). Mg(2+) or Mn(2+)
CC       have no effect on ceramidase activity.
CC       {ECO:0000269|PubMed:20089856}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=81 uM for D-erythro-C(24:1)-ceramide (at 37 degrees Celsius
CC         and pH 9.0) {ECO:0000269|PubMed:20089856};
CC         Vmax=27 pmol/min/mg enzyme with D-erythro-C(24:1)-ceramide as
CC         substrate {ECO:0000269|PubMed:20089856};
CC       pH dependence:
CC         Optimum pH is 7.5-9.0. {ECO:0000269|PubMed:20089856};
CC   -!- SUBCELLULAR LOCATION: Golgi apparatus membrane
CC       {ECO:0000269|PubMed:16940153, ECO:0000269|PubMed:20089856}; Multi-
CC       pass membrane protein {ECO:0000269|PubMed:16940153,
CC       ECO:0000269|PubMed:20089856}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q5QJU3-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q5QJU3-2; Sequence=VSP_020033;
CC       Name=3;
CC         IsoId=Q5QJU3-3; Sequence=VSP_020033, VSP_020034, VSP_020035;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Highly expressed in placenta.
CC       {ECO:0000269|PubMed:16940153}.
CC   -!- SIMILARITY: Belongs to the alkaline ceramidase family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY312516; AAQ85132.1; -; mRNA.
DR   EMBL; AF370405; AAQ15241.1; -; mRNA.
DR   EMBL; AL158206; CAH73022.1; -; Genomic_DNA.
DR   EMBL; AL391834; CAH73022.1; JOINED; Genomic_DNA.
DR   EMBL; AL391834; CAM21146.1; -; Genomic_DNA.
DR   EMBL; AL158206; CAM21146.1; JOINED; Genomic_DNA.
DR   EMBL; BC092487; AAH92487.1; -; mRNA.
DR   CCDS; CCDS34992.1; -. [Q5QJU3-1]
DR   RefSeq; NP_001010887.2; NM_001010887.2. [Q5QJU3-1]
DR   RefSeq; XP_005251505.1; XM_005251448.3. [Q5QJU3-2]
DR   RefSeq; XP_016870183.1; XM_017014694.1. [Q5QJU3-2]
DR   UniGene; Hs.41379; -.
DR   UniGene; Hs.99785; -.
DR   ProteinModelPortal; Q5QJU3; -.
DR   IntAct; Q5QJU3; 1.
DR   STRING; 9606.ENSP00000342609; -.
DR   BindingDB; Q5QJU3; -.
DR   ChEMBL; CHEMBL2331067; -.
DR   SwissLipids; SLP:000000164; -.
DR   BioMuta; ACER2; -.
DR   DMDM; 110832756; -.
DR   PaxDb; Q5QJU3; -.
DR   PRIDE; Q5QJU3; -.
DR   Ensembl; ENST00000340967; ENSP00000342609; ENSG00000177076. [Q5QJU3-1]
DR   GeneID; 340485; -.
DR   KEGG; hsa:340485; -.
DR   UCSC; uc003zny.2; human. [Q5QJU3-1]
DR   CTD; 340485; -.
DR   DisGeNET; 340485; -.
DR   GeneCards; ACER2; -.
DR   H-InvDB; HIX0025758; -.
DR   HGNC; HGNC:23675; ACER2.
DR   MIM; 613492; gene.
DR   neXtProt; NX_Q5QJU3; -.
DR   OpenTargets; ENSG00000177076; -.
DR   PharmGKB; PA164714853; -.
DR   eggNOG; KOG2329; Eukaryota.
DR   eggNOG; ENOG4111RPN; LUCA.
DR   GeneTree; ENSGT00730000110920; -.
DR   HOGENOM; HOG000220878; -.
DR   InParanoid; Q5QJU3; -.
DR   KO; K01441; -.
DR   OMA; KFWPSER; -.
DR   OrthoDB; EOG091G0HT1; -.
DR   PhylomeDB; Q5QJU3; -.
DR   TreeFam; TF313019; -.
DR   BRENDA; 3.5.1.23; 2681.
DR   Reactome; R-HSA-1660661; Sphingolipid de novo biosynthesis.
DR   SABIO-RK; Q5QJU3; -.
DR   ChiTaRS; ACER2; human.
DR   GeneWiki; ACER2; -.
DR   GenomeRNAi; 340485; -.
DR   PRO; PR:Q5QJU3; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000177076; -.
DR   CleanEx; HS_ACER2; -.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0030173; C:integral component of Golgi membrane; IDA:UniProtKB.
DR   GO; GO:0017040; F:ceramidase activity; IDA:UniProtKB.
DR   GO; GO:0071633; F:dihydroceramidase activity; IDA:BHF-UCL.
DR   GO; GO:0006919; P:activation of cysteine-type endopeptidase activity involved in apoptotic process; IMP:BHF-UCL.
DR   GO; GO:0035690; P:cellular response to drug; IEP:BHF-UCL.
DR   GO; GO:0006672; P:ceramide metabolic process; IEA:InterPro.
DR   GO; GO:0033629; P:negative regulation of cell adhesion mediated by integrin; IDA:UniProtKB.
DR   GO; GO:0001953; P:negative regulation of cell-matrix adhesion; IDA:UniProtKB.
DR   GO; GO:0090285; P:negative regulation of protein glycosylation in Golgi; IMP:UniProtKB.
DR   GO; GO:0010942; P:positive regulation of cell death; IMP:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:UniProtKB.
DR   GO; GO:0032526; P:response to retinoic acid; IDA:UniProtKB.
DR   GO; GO:0030148; P:sphingolipid biosynthetic process; TAS:Reactome.
DR   GO; GO:0046512; P:sphingosine biosynthetic process; IDA:UniProtKB.
DR   InterPro; IPR008901; Ceramidase.
DR   Pfam; PF05875; Ceramidase; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Complete proteome; Glycoprotein;
KW   Golgi apparatus; Hydrolase; Lipid metabolism; Membrane; Polymorphism;
KW   Reference proteome; Transmembrane; Transmembrane helix.
FT   CHAIN         1    275       Alkaline ceramidase 2.
FT                                /FTId=PRO_0000247748.
FT   TOPO_DOM      1     32       Lumenal. {ECO:0000255}.
FT   TRANSMEM     33     53       Helical. {ECO:0000255}.
FT   TOPO_DOM     54     62       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     63     83       Helical. {ECO:0000255}.
FT   TOPO_DOM     84     86       Lumenal. {ECO:0000255}.
FT   TRANSMEM     87    107       Helical. {ECO:0000255}.
FT   TOPO_DOM    108    124       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    125    142       Helical. {ECO:0000255}.
FT   TOPO_DOM    143    143       Lumenal. {ECO:0000255}.
FT   TRANSMEM    144    164       Helical. {ECO:0000255}.
FT   TOPO_DOM    165    173       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    174    194       Helical. {ECO:0000255}.
FT   TOPO_DOM    195    211       Lumenal. {ECO:0000255}.
FT   TRANSMEM    212    232       Helical. {ECO:0000255}.
FT   TOPO_DOM    233    275       Cytoplasmic. {ECO:0000255}.
FT   REGION        1     13       Essential for localization in the Golgi
FT                                apparatus and for activity.
FT   CARBOHYD     23     23       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   VAR_SEQ       1     49       Missing (in isoform 2 and isoform 3).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:15498874}.
FT                                /FTId=VSP_020033.
FT   VAR_SEQ     169    189       CDNMRVFKLGLFSGLWWTLAL -> HERNQRRRHRKGGQQG
FT                                GGDKV (in isoform 3).
FT                                {ECO:0000303|PubMed:15498874}.
FT                                /FTId=VSP_020034.
FT   VAR_SEQ     190    275       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15498874}.
FT                                /FTId=VSP_020035.
FT   VARIANT     134    134       A -> V (in dbSNP:rs10964136).
FT                                /FTId=VAR_027150.
FT   CONFLICT    274    274       I -> T (in Ref. 1; AAQ85132).
FT                                {ECO:0000305}.
SQ   SEQUENCE   275 AA;  31309 MW;  56FD619B53C296B1 CRC64;
     MGAPHWWDQL QAGSSEVDWC EDNYTIVPAI AEFYNTISNV LFFILPPICM CLFRQYATCF
     NSGIYLIWTL LVVVGIGSVY FHATLSFLGQ MLDELAVLWV LMCALAMWFP RRYLPKIFRN
     DRGRFKVVVS VLSAVTTCLA FVKPAINNIS LMTLGVPCTA LLIAELKRCD NMRVFKLGLF
     SGLWWTLALF CWISDRAFCE LLSSFNFPYL HCMWHILICL AAYLGCVCFA YFDAASEIPE
     QGPVIKFWPN EKWAFIGVPY VSLLCANKKS SVKIT
//
